Hormone replacement therapy (HRT) for oestrogen deficiency symptoms in postmenopausal women at least 12 months since last menses. Prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis. (See also section 4.4) The experience in treating women older than 65 years is limited.
Hormone replacement therapy (HRT) for oestrogen deficiency symptoms in postmenopausal women at least 12 months since last menses. The experience in treating women older than 65 years is limited.
Hormone replacement therapy (HRT) for oestrogen deficiency symptoms in postmenopausal women at least 6 months since last menses. Prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis. (See also section 4.4) The experience in treating women older than 65 years is limited.
Hormone replacement therapy (HRT) for oestrogen deficiency symptoms in post-menopausal women more than 6 months post-menopause (or 18 months since last period). Prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis. (See also Section 4.4) The experience treating women older than 65 years is limited.
Hormone Replacement Therapy (HRT) for oestrogen deficiency symptoms in women one year since last menses. Prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis (see also Section 4.4).The experience of treating women older than 65 years is limited.
Hormone Replacement Therapy (HRT) for oestrogen deficiency symptoms in postmenopausal women more than one year after menopause. Experience of treating women older than 65 years is limited.
Hormone replacement therapy (HRT) for oestrogen deficiency symptoms in peri- and post-menopausal women. Prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis. (See also Section 4.4) The experience treating women older than 65 years is limited.
Merck Inc., known as MSD outside of the United States and Canada, announced that the FDA has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with resectable (tumors greater than 4 centimeters [cm] or node positive) non-small cell lung cancer (NSCLC) in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.
The purpose of this article is to establish the Vitamin D role on immunomodulation, inflammatory and autoimmune processes in GN.